source
- Mirum readies FDA filing after positive Phase 3 results for hepatitis D therapyMirum Pharmaceuticals announced that its hepatitis D candidate has met its primary goals in the second of two pivotal studies. The company said the data support moving the product toward regulatory…
- Beam Therapeutics' base-edited sickle cell therapy shows success in Phase 1/2 trialBeam Therapeutics announced on Tuesday that its base-edited gene therapy for sickle cell disease met its primary endpoints in a Phase 1/2 study. The trial demonstrated that a single administration…